vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Innovex International, Inc. (INVX). Click either name above to swap in a different company.
Innovex International, Inc. is the larger business by last-quarter revenue ($273.6M vs $268.1M, roughly 1.0× ACADIA PHARMACEUTICALS INC). Innovex International, Inc. runs the higher net margin — 5.1% vs 1.4%, a 3.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.7% vs 9.1%). Over the past eight quarters, Innovex International, Inc.'s revenue compounded faster (46.2% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
ACAD vs INVX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $273.6M |
| Net Profit | $3.6M | $14.0M |
| Gross Margin | — | 28.9% |
| Operating Margin | -1.7% | 9.4% |
| Net Margin | 1.4% | 5.1% |
| Revenue YoY | 9.7% | 9.1% |
| Net Profit YoY | — | -56.1% |
| EPS (diluted) | $0.02 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | — | ||
| Q4 25 | $284.0M | $273.6M | ||
| Q3 25 | $278.6M | $240.0M | ||
| Q2 25 | $264.6M | $224.2M | ||
| Q1 25 | $244.3M | $240.4M | ||
| Q4 24 | $259.6M | $250.7M | ||
| Q3 24 | $250.4M | $151.8M | ||
| Q2 24 | $242.0M | $130.3M |
| Q1 26 | $3.6M | — | ||
| Q4 25 | $273.6M | $14.0M | ||
| Q3 25 | $71.8M | $39.2M | ||
| Q2 25 | $26.7M | $15.3M | ||
| Q1 25 | $19.0M | $14.8M | ||
| Q4 24 | $143.7M | $31.8M | ||
| Q3 24 | $32.8M | $82.6M | ||
| Q2 24 | $33.4M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | 28.9% | ||
| Q3 25 | 92.2% | 31.6% | ||
| Q2 25 | 92.2% | 32.0% | ||
| Q1 25 | 91.7% | 31.8% | ||
| Q4 24 | 91.6% | 33.9% | ||
| Q3 24 | 92.5% | 34.7% | ||
| Q2 24 | 92.5% | 35.3% |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | 9.4% | ||
| Q3 25 | 12.8% | 26.0% | ||
| Q2 25 | 12.2% | 10.1% | ||
| Q1 25 | 7.9% | 9.1% | ||
| Q4 24 | 59.1% | 10.7% | ||
| Q3 24 | 12.6% | -8.7% | ||
| Q2 24 | 12.6% | 10.0% |
| Q1 26 | 1.4% | — | ||
| Q4 25 | 96.3% | 5.1% | ||
| Q3 25 | 25.8% | 16.3% | ||
| Q2 25 | 10.1% | 6.8% | ||
| Q1 25 | 7.8% | 6.1% | ||
| Q4 24 | 55.4% | 12.7% | ||
| Q3 24 | 13.1% | 54.4% | ||
| Q2 24 | 13.8% | 7.3% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | $0.20 | ||
| Q3 25 | $0.42 | $0.57 | ||
| Q2 25 | $0.16 | $0.22 | ||
| Q1 25 | $0.11 | $0.21 | ||
| Q4 24 | $0.86 | $-0.03 | ||
| Q3 24 | $0.20 | $1.99 | ||
| Q2 24 | $0.20 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $18.9M |
| Stockholders' EquityBook value | — | $1.1B |
| Total Assets | $1.6B | $1.3B |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | $185.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $18.9M | ||
| Q3 25 | — | $20.1M | ||
| Q2 25 | — | $34.8M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $24.9M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $917.3M | $1.0B | ||
| Q2 25 | $822.4M | $995.6M | ||
| Q1 25 | $765.2M | $978.4M | ||
| Q4 24 | $732.8M | $958.2M | ||
| Q3 24 | $577.2M | $904.4M | ||
| Q2 24 | $516.7M | $352.5M |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $1.3B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $976.9M | $1.1B | ||
| Q2 24 | $914.1M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.03× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $52.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.74× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $52.2M | ||
| Q3 25 | $74.3M | $48.4M | ||
| Q2 25 | $64.0M | $59.2M | ||
| Q1 25 | $20.3M | $31.1M | ||
| Q4 24 | $40.4M | $36.3M | ||
| Q3 24 | $63.2M | $21.7M | ||
| Q2 24 | $25.0M | $22.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $16.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | 12.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | 4.7% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.74× | ||
| Q3 25 | 1.03× | 1.23× | ||
| Q2 25 | 2.40× | 3.86× | ||
| Q1 25 | 1.07× | 2.11× | ||
| Q4 24 | 0.28× | 1.14× | ||
| Q3 24 | 1.93× | 0.26× | ||
| Q2 24 | 0.75× | 2.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
Segment breakdown not available.
INVX
| Products | $202.7M | 74% |
| Leasing | $42.3M | 15% |
| Services | $28.6M | 10% |
